Dr. Melanie Rolli

Biography

• Joined Helsinn in June 2022 and appointed Group Chief Operating Officer
• +20 years’ experience in the pharmaceutical and biotech sectors in executive and non-executive roles, general management, business & fundraising and vision & strategy development
• Prior to Helsinn served as Chief Executive Officer at both AELIX Therapeutics and PIQUR Therapeutics, developing molecules in oncology and dermatology
• 14 years at Novartis Pharma in various leadership roles across drug development and medical affairs, focused on oncology, including being an integral part of the GSK Oncology Portfolio Integration into Novartis Oncology Business Unit
• Completed an MD at Heidelberg University, Germany and held a postdoctoral fellowship in cancer research at SCRIPPS Research Institute for Molecular and Experimental Medicine, USA.